New Delhi, March 12 Aurobindo Pharma announced on Thursday that it has received an inspection report from the US health regulator, classifying its wholly-owned subsidiary's manufacturing unit in Andhra Pradesh as having a "Voluntary Action Indicated" (VAI) classification, which indicates satisfactory conditions.
According to the US Food and Drug Administration (USFDA), a VAI classification means that objectionable conditions or practices were found, but the agency is not prepared to take or recommend any administrative or regulatory action.
The US Food and Drug Administration (USFDA) inspected Unit-IV of APL Healthcare Ltd in the Nellore district from December 8-17, 2025.
At the end of the inspection, a Form 483 was issued with five observations.
"The unit has now received an Establishment Inspection Report (EIR) classifying the facility as Voluntary Action Indicated (VAI), and this inspection is now closed," said the Hyderabad-based drugmaker in a regulatory filing.
Aurobindo shares on Thursday closed 0.67 per cent up at Rs 1,313.30 apiece on the BSE.
